Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CleanSpace HoldingsASX:CSX 27 EBITDA Margin % is 22.63% as of Dec. 2025. GuruFocus rates ASX:CSX with a GF Score™ of 27/100 and a GF Value™ of A$0.55 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, CleanSpace Holdings ranks better than 59.51% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CleanSpace Holdings EBITDA Margin % Related Terms
CleanSpace Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CleanSpace Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CSX vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, CleanSpace Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CleanSpace Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CleanSpace Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CleanSpace Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CleanSpace Holdings (ASX:CSX) has a EBITDA Margin % of 22.63% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CleanSpace Holdings and its competitors. According to the industry distribution chart, CleanSpace Holdings ranks #330 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 40.5%.
Is CleanSpace Holdings' EBITDA Margin % too high?
CleanSpace Holdings' current EBITDA Margin % is 22.63%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. CleanSpace Holdings' value of 22.63% is 202.5% above this industry median. Based on the distribution chart, CleanSpace Holdings ranks #330 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CleanSpace Holdings has a GF Score™ of 27/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CleanSpace Holdings' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CleanSpace Holdings ranks #330 out of 815 companies for EBITDA Margin %. This puts CleanSpace Holdings in the upper half of its industry. The industry median EBITDA Margin % is 7.48. CleanSpace Holdings' value of 22.63% is 202.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CleanSpace Holdings's current EBITDA Margin % of 22.63% is 202.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CleanSpace Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CleanSpace Holdings's current EBITDA Margin % is 22.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CleanSpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, CleanSpace Holdings (ASX:CSX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.55, compared to a current price of A$0.40 — trading 28.2% below its estimated fair value. The current EBITDA Margin % is 22.63% and 202.5% above the Medical Devices & Instruments industry median of 7.48. CleanSpace Holdings' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CleanSpace Holdings (ASX:CSX), the current EBITDA Margin % is 22.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CleanSpace Holdings (ASX:CSX) Overvalued in 2026?
Based on GuruFocus' analysis, CleanSpace Holdings stock appears to be undervalued.
The current stock price of A$0.40 is trading 28.2% below its estimated GF Value™ of A$0.55.
GuruFocus considers CleanSpace Holdings to be Modestly Undervalued.
Key valuation signals for ASX:CSX:
EBITDA Margin %: 22.63%
GF Value™: A$0.55 vs. price of A$0.40 (28.2% below fair value)
Industry Position: 202.5% above the Medical Devices & Instruments median (#330 of 815)
No single metric tells the full story. See the ASX:CSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CleanSpace Holdings Ltd manufactures and sells respirators and related products and services. Its products include Compare, CleanSpace HALO, CleanSpace ULTRA, Masks, Filters, and Compatible Products. The company's operating segment is based on regions that include, Europe, Asia, and North America, and the majority of its revenue is generated from Europe.
27GF Score
Get the complete analysis for ASX:CSX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CSX has been successfully added to your 
